Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Bonate

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2017
Scientific white paper on concentration-QTc modelingChristine Garnett, Peter L Bonate, Qianyu Dang, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2008
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primatesLindsay B Kilburn, Peter L Bonate, Susan M Blaney, et al.
Journal of Clinical Pharmacology|September 25, 2010
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteersM Judith Peterschmitt, Amy Burke, Larry Blankstein, et al.
Investigational New Drugs|September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumorsAung Naing, Razelle Kurzrock, Laurel M Adams, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous FungiAmit V Desai, Laura L Kovanda, William W Hope, et al.
Journal of Clinical Pharmacology|October 22, 2004
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemiaPeter L Bonate, Adam Craig, Paul Gaynon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.
The Pediatric Infectious Disease Journal|May 16, 2018
Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical TrialsLaura L Kovanda, Thomas J Walsh, Daniel K Benjamin, et al.
Clinical Pharmacology in Drug Development|March 24, 2020
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy SubjectsPeter L Bonate, Charles Van Sant, Kathy Cho, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 8, 2025
A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With PembrolizumabAkihiro Yamada, Mary P Choules, Frances A Brightman, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2017
Scientific white paper on concentration-QTc modelingChristine Garnett, Peter L Bonate, Qianyu Dang, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2008
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primatesLindsay B Kilburn, Peter L Bonate, Susan M Blaney, et al.
Journal of Clinical Pharmacology|September 25, 2010
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteersM Judith Peterschmitt, Amy Burke, Larry Blankstein, et al.
Investigational New Drugs|September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumorsAung Naing, Razelle Kurzrock, Laurel M Adams, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous FungiAmit V Desai, Laura L Kovanda, William W Hope, et al.
Journal of Clinical Pharmacology|October 22, 2004
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemiaPeter L Bonate, Adam Craig, Paul Gaynon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.
The Pediatric Infectious Disease Journal|May 16, 2018
Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical TrialsLaura L Kovanda, Thomas J Walsh, Daniel K Benjamin, et al.
Clinical Pharmacology in Drug Development|March 24, 2020
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy SubjectsPeter L Bonate, Charles Van Sant, Kathy Cho, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 8, 2025
A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With PembrolizumabAkihiro Yamada, Mary P Choules, Frances A Brightman, et al.
Pageof 7